Prescribing information

 

FOR WOMEN WITH ADVANCED BREAST CANCER, TIME IS PRECIOUS

KISQALI is indicated for the treatment of women with hormone receptor (HR)−positive, human epidermal growth factor receptor 2 (HER2)−negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.* In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1

*KISQALI is not recommended to be used in combination with tamoxifen.1

 

With KISQALI + ET*, you can give your HR+/HER2− aBC patients more
time worth having1–10

 

More time with their loved ones

  • KISQALI + ET* is the only CDK4/6i to show statistically significant improvements in OS in three phase III trials3,4,10
moving clock to accompany description for 'More time with their loved ones'
 

The quality time they need

Improved or preserved quality of life vs fulvestrant/NSAI alone5,6

Quality rosette to accompany description for 'The quality time they need'
 

Time with manageable side effects

Manageable and consistent safety profile1–4,7–15

Glowing cross in someone's hands to accompany description for 'Time with manageable side effects'
 

 

*KISQALI is not recommended to be used in combination with tamoxifen.1

PLEASE SELECT A PATIENT POPULATION AND SETTING TO FIND OUT HOW KISQALI CAN HELP WOMEN WITH HR+/HER2− aBC

 

Premenopausal women

KISQALI + non-steroidal aromatase inhibitor (NSAI) in first-line premenopausal patient population.

Show me more

Postmenopausal women

KISQALI + fulvestrant in postmenopausal patient population.

Show me more

Postmenopausal women

KISQALI + aromatase inhibitor (AI) in first-line postmenopausal patient population.

Show me more

SAFETY

Learn about KISQALI’s safety profile

 

KISQALI DOSING & MONITORING

Find out how to get started with KISQALI

 

RESOURCES

Access HCP and patient materials

 

aBC, advanced breast cancer; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; ET, endocrine therapy; HR+/HER2-, hormone receptor-positive/human epidermal growth factor receptor 2-negative; LHRH, luteinising hormone-releasing hormone; NSAI, non-steroidal aromatase inhibitor; OS, overall survival.

  1. KISQALI (ribociclib). Summary of Product Characteristics.
  2. Slamon DJ, et al. J Clin Oncol. 2018;36(24):2465–2472.
  3. Slamon DJ, et al. N Engl J Med. 2020;382(6):514–524.
  4. Im S-A, et al. N Engl J Med. 2019;381(4):307–316. 
  5. Harbeck N, et al. Ther Adv Med Oncol. 2020;12:1758835920943065.
  6. Fasching P, et al. Breast. 2020;54:148–154.
  7. Lu Y-S, et al. Clin Cancer Res. 2022;2(5):851–859.
  8. De Laurentiis M, et al. J Clin Oncol. 2020;38(15):1055–1055.
  9. De Laurentiis M, et al. J Clin Oncol. 2018;36(15):1056–1056.
  10. Hortobagyi GN, et al. N Engl J Med. 2022;386(10):942–950.
  11. Hortobagyi GN, et al. Ann Oncol. 2018;29(7):1541–1547. 
  12. Tripathy D, et al. Lancet Oncol. 2018;19(7):904–915
  13. Bardia A, et al. Poster 330P. Presentation at European Society for Medical Oncology Congress, 19-23 October 2018, Munich, Germany.
  14. Hortobagyi GN, et al. N Engl J Med. 2016;375(18):1738–1748
  15. Slamon DJ, et al. Presented at ASCO Annual Meeting, 4–8 June 2021.
Rate this content: 
Average: 3.5 (16 votes)
UK | August 2022 | 126157-2

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]